|
시장보고서
상품코드
1747313
조울증 기분 안정제 시장 : 약제 유형별, 적응증별, 투여 경로별, 환자 속성별, 유통 채널별, 지역별Bipolar Disorder Mood Stabilizers Market, By Drug Type, By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 조울증 기분 안정제 시장은 2025년에는 22억 2,000만 달러, 2032년까지는 26억 4,000만 달러에 이를 것으로 예측되며, 2025-2032년 연평균 복합 성장률(CAGR)은 2.5%를 보일 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 22억 2,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간(2025-2032년) CAGR | 2.50% | 2032년 금액 예측 | 26억 4,000만 달러 |
조울증으로도 알려진 양극성 장애는 기분, 에너지, 활동 수준, 일상 업무 수행 능력에 비정상적인 변화를 일으키는 뇌 질환입니다. 항우울제는 양극성 장애로 인한 극단적인 기분 변화를 예방하거나 치료하기 위해 사용되는 약물의 일종입니다. 전 세계적으로 양극성 장애의 유병률이 증가하고 효과적인 치료 옵션에 대한 인식이 높아짐에 따라, 세계 양극성 장애 기분 안정제 시장은 지난 몇 년 동안 큰 견인차 역할을 해왔습니다. 또한, 새로운 치료법을 개발하기 위한 제약사들의 R&D 투자 증가도 시장 성장에 기여하고 있습니다.
시장 역학
세계 양극성 장애 기분 안정제 시장은 주로 유전적 요인과 외상성 생활 사건 및 약물 남용과 같은 환경적 요인으로 인한 양극성 장애의 유병률 증가에 의해 주도되고 있으며, 2024년 7월에 발표된 WHO 통계에 따르면 전 세계적으로 4,500만 명 이상이 양극성 장애를 앓고 있다고 합니다. 을 앓고 있습니다. 또한, 사용 가능한 치료 옵션에 대한 인식이 높아지고 의료비 지출이 증가함에 따라 더 많은 환자들이 의료 지원을 요청하고 있습니다. 한편, 지속적인 기술 혁신과 더 효과적이고 내약성이 개선된 새로운 약물 제제의 도입은 시장 확대를 촉진하고 있습니다. 그러나 저개발국에서는 정신장애의 진단 및 치료율이 낮기 때문에 시장 잠재력은 아직 미개척 상태입니다. 또한, 브랜드 의약품의 높은 비용도 가격에 민감한 시장에서의 채택을 제한하고 있습니다. 그럼에도 불구하고, 특히 치료 저항성 환자를 대상으로 한 첨단 약물에 대한 임상시험이 진행 중이기 때문에 예측 기간 동안 새로운 기회가 창출될 것으로 예측됩니다.
본 조사의 주요 특징
- 세계의 양극성 장애 기분안정제(조울증 치료제) 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 양극성 장애 기분 안정제 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 양극성 장애 기분 안정제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 양극성 장애 기분 안정제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
- 업계 동향
제4장 세계의 조울증 기분 안정제 시장, 약제 유형별, 2020년-2032년
- Lithium
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- 기타(병용요법 등)
제5장 세계의 조울증 기분 안정제 시장, 적응증별, 2020년-2032년
- 양극성 I형 장애
- 양극성 II 장애
- 기분 순환성 장애
- 혼합성 조울증
- 급속 순환형 조울증
- 기타
제6장 세계의 조울증 기분 안정제 시장, 투여 경로별, 2020년-2032년
- 경구
- 비경구/주사제
- 경피
- 기타
제7장 세계의 조울증 기분 안정제 시장, 환자 속성별, 2020년-2032년
- 연령층
- 어린이 및 청소년
- 성인
- 고령자
- 성별
- 남성
- 여성
제8장 세계의 조울증 기분 안정제 시장, 유통 채널별, 2020년-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제9장 세계의 조울증 기분 안정제 시장, 지역별, 2020년-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제10장 경쟁 구도
- Eli Lilly and Company
- AstraZeneca PLC
- Johnson & Johnson
- Pfizer Inc.
- AbbVie Inc.
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi S.A.
- Merck & Co.
- Teva Pharmaceutical Industries
- Novartis AG
- Otsuka Pharmaceutical
- Lundbeck A/S
- Takeda Pharmaceutical Company
- Alkermes plc
제11장 애널리스트의 제안
- Wheel of Fortune
- 애널리스트의 견해
- Coherent Opportunity Map
제12장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사에 대해
The Global Bipolar Disorder Mood Stabilizers Market is estimated to be valued at USD 2.22 Bn in 2025 and is expected to reach USD 2.64 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 2.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 2.22 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 2.50% | 2032 Value Projection: | USD 2.64 Bn |
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Mood stabilizers are a class of drugs used to prevent or treat the extreme mood swings associated with bipolar disorder. The global bipolar disorder mood stabilizers market has been gaining significant traction over the past few years, owing to the rising prevalence of bipolar disorder worldwide and growing awareness regarding its effective treatment options. Increasing R&D investments by pharmaceutical companies to develop novel treatment alternatives are also propelling the market growth.
Market Dynamics
The global bipolar disorder mood stabilizers market is primarily driven by the growing prevalence of bipolar disorder caused by genetic and environmental factors such as traumatic life events and substance abuse. As per WHO statistics released in July 2024, over 45 million people worldwide suffer from bipolar disorder. Furthermore, rising awareness about available treatment options and increased healthcare spending are encouraging more patients to seek medical help. Meanwhile, continuous innovations and introduction of new drug formulations with higher efficacy and improved tolerability are helping expand the market reach. However, the market potential is still untapped in underdeveloped economies due to low diagnosis and treatment rates of mental disorders. High costs of branded drugs also limit their adoption in price-sensitive markets. Nonetheless, ongoing clinical trials for advanced drugs, especially for treatment-resistant patients, are expected to introduce new opportunities during the forecast period.
Key Features of the Study
- This report provides in-depth analysis of the global bipolar disorder mood stabilizers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bipolar disorder mood stabilizers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eli Lilly and Company, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi S.A., Merck & Co., Teva Pharmaceutical Industries, Novartis AG, Otsuka Pharmaceutical, H. Lundbeck A/S, Takeda Pharmaceutical Company, and Alkermes plc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bipolar disorder mood stabilizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder mood stabilizers market
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Lithium
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- Others (Combination Therapies, etc.)
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
- Mixed Features Bipolar Disorder
- Rapid Cycling Bipolar Disorder
- Others
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral/Injectable
- Transdermal
- Others
- Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Children and adolescents
- Adults
- Elderly
- Gender
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Eli Lilly and Company
- AstraZeneca PLC
- Johnson & Johnson
- Pfizer Inc.
- AbbVie Inc.
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi S.A.
- Merck & Co.
- Teva Pharmaceutical Industries
- Novartis AG
- Otsuka Pharmaceutical
- Lundbeck A/S
- Takeda Pharmaceutical Company
- Alkermes plc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Bipolar Disorder Mood Stabilizers Market, By Drug Type
- Global Bipolar Disorder Mood Stabilizers Market, By Indication
- Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration
- Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics
- Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel
- Global Bipolar Disorder Mood Stabilizers Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Bipolar Disorder Mood Stabilizers Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Lithium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Combination Therapies, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Bipolar Disorder Mood Stabilizers Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Bipolar I Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bipolar II Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cyclothymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Features Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rapid Cycling Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral/Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Children and adolescents
- Adults
- Elderly
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Male
- Female
8. Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Bipolar Disorder Mood Stabilizers Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alkermes plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
